ArvindBagga India

Upload Picture

First name

Arvind

Last name

Bagga

Institution

Country

India

Friday, February 7, 2025

Time	Session

9:45 a.m. 11:15 a.m.	CKD-MBD Insights and Innovations for 2025 and Beyond: No Bone Left Uncovered LF01 ArvindBagga Chair arvindbagga@hotmail.comIndia UttaraDas Chair uttaradas806@gmail.comIndiaAll IndiaInstitute of Medical Science Mangalagiri What Should a Clinician Know About CKD-MBD in 2025? LF01-01 HanneJoergensen Speaker hsjorgensen@clin.au.dkDenmarkAarhus University CKD-MBD in Children and Young Adults: What's the Difference? LF01-02 SukanyaGovindan Speaker IndiaMehta Children's Hospitals and MGM healthcare, Chennai, India Progress in CKD-driven Vascular Calcification: From Bench to Bedside LF01-03 MarcVervloet Speaker NetherlandsRadboud University Medical center, The Netherlands How to Use Serum Biomarkers for Optimal Management of CKD-MBD LF01-04 SandroMazzaferro Speaker sandro.mazzaferro@uniroma1.itItalySapienza University of Rome, Italy Q&A LF01-05 Gulmohar Hall 302	State of the Art Insights Into Pregnancy and Pediatric Thrombotic Microangiopathies IK1001 ArvindBagga Chair arvindbagga@hotmail.comIndia DavidKavanagh Chair United KingdomNational Renal Complement Therapeutics Centre VinayRathore Chair IndiaAll India Institute of Medical Sciences- Raipur Outcomes From the ISN Haemolytic Uraemic Syndromes Forum: A Comprehensive Review IK1001-01 DavidKavanagh Speaker United KingdomNational Renal Complement Therapeutics Centre Differential Diagnosis and Treatment of TMAs in Pregnancy IK1001-02 ShilpanjaliJesudason Speaker AustraliaRoyal Adelaide Hospital and Adelaide University, Australia Factor H Autoantibodies in aHUS IK1001-03 AditiSinha Speaker aditisinhaaiims@gmail.comIndiaDepartment of Pediatrics, All India Institute of Medical Sciences aHUS in Paediatric Populations IK1001-04 Lap Tak Alison MA Speaker Hong Kong, ChinaHong Kong Children\'s Hospital Q&A IK1001-05 Parijat Hall 201